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In this issue of Immunity, Teng et al. (2008) and Dorsett et al. (2008) report that activation-induced cytidine
deaminase in B cells is repressed by microRNA-155. Relief of repression is associated with defective affinity
maturation and increased Myc-Igh translocations.One of the most stunning recent develop-
ments in molecular biology is the discov-
ery of microRNAs (miRNAs) and the
realization that these hitherto unappreci-
ated entities play pervasive roles in the
regulation of gene expression. The sheer
profusion of miRNAs and the multiplicity
of their targets suggests a staggering
ramification of regulatory interactions;
mammalian genomes encode at least
several hundred and perhaps several
thousand miRNAs, each of which might
regulate scores of genes through direct
interactions and many more through indi-
rect effects. A pair of papers published in
this issue of Immunity now cuts through
this web of complexity by asking what
happens when a single target gene—en-
coding activation-induced cytidine deam-
inase (AID)—is relieved of its regulation by
a specific miRNA.
Despite their diversity, miRNAs are
produced by common mechanisms and
exert their effects in similar ways (Bartel,
2004). The genes that encode miRNAs
are transcribed into primary transcripts
(pri-miRNAs), from which pre-miRNAs
are excised. These stem-loop structures
are further trimmed to duplexes of about
22 basepairs by the ribonuclease Dicer,
and one of the two strands of the du-
plex—the functional miRNA—becomes
associated with the RNA-induced silenc-
ing complex (RISC). Specific basepairing
between the miRNA and the transcript of
a target gene then represses expression,
either by promoting mRNA degradation
or by suppressing translation. The accu-
mulation of a particular miRNA is itself
controlled at several points, including
production of the the primary transcript
and processing of pri- and pre-miRNAs.
The microRNA miR-155 has drawn
particular attention from those interested596 Immunity 28, May 2008 ª2008 Elsevier Iin B cell biology (Figure 1). The first hints
of its importance predate the discovery
of vertebrate miRNAs. Induction of B cell
lymphomas by avian leukosis virus (ALV)
in chickens was associated with integra-
tion of ALV into a locus called Bic; the cul-
prit turned out to be aBic noncoding exon
whose overexpression was driven by an
ALV promoter (Tam et al., 2002). The on-
cogenic activity of this transcript required
a conserved region that was later found
to span miR-155. Many B cell lymphomas
overexpress Bic or miR-155, and B cell-
specific expression of a miR-155 trans-
gene promotes polyclonal B cell prolifera-
tion in mice (Costinean et al., 2006). In
contrast, inefficient processing of primary
Bic transcripts contributes to decreased
accumulation of miR-155 in Burkitt lym-
phoma (Kluiver et al., 2007).
B cells, T cells, macrophages, and den-
dritic cells can all express miR-155. Given
its presence in multiple cell types and its
potential to repress scores of target tran-
scripts, ablation of miR-155 would be
expected to have broad effects on gene
expression and immune function. This is
indeed the case. Mice lacking miR-155
are viable and undergo normal central-
lymphoid development but exhibit sub-
stantial reductions in germinal center
(GC) B cells with accompanying defects
in B and T cell function (Rodriguez et al.,
2007; Thai et al., 2007). The miR-155-de-
ficient mice were shown to have a B cell-
intrinsic defect in the generation of
high-affinity antibody responses to a T
cell-dependent antigen (Vigorito et al.,
2007). These observations suggested
that miR-155 has particular importance
for GC B cell development.
The specific mechanisms underlying
these effects, however, would have been
impossible to discern. About 60 putativenc.miR-155 targets were overexpressed in
miR-155-deficient B cells treated with
LPS and IL4—a regimen that mimics as-
pects of B cell activation in GCs. Among
these was the gene encoding the tran-
scriptional activator PU.1, which was
validated as a target for miR-155 (Vigorito
et al., 2007). But PU.1 was but one of
many putative targets; more than a hun-
dred additional genes were affected indi-
rectly. Incidentally, the gene that encodes
AID (Aicda) was also found to contain
a target site for miR-155, and expression
was also increased in miR-155-deficient
B cells. Which leads us to the work
described in this issue of Immunity.
The present papers describe the abla-
tion in vivo of an miRNA target site within
a single transcript—in this case, the tran-
script that encodes AID. AID initiates so-
matic hypermutation (SHM) in GC B cells
and is therefore essential for secondary
diversification of the antibody repertoire
in mice and humans. AID is also essential
for class-switch recombination (CSR),
which engrafts variable regions of particu-
lar specificity and affinity onto heavy-
chain constant regions with diverse
effector functions. Both of these functions
of AID stem from its ability to catalyze de-
amination of cytosine to uracil; this leads
to DNA cleavage through the consecutive
actions of uracil DNA glycosidase and
APE endonuclease.
Teng and coworkers (Teng et al., 2008)
begin with the observation that miR-155 is
induced in primary B cells induced by LPS
and IL-4 to initiateCSR.Extendingprevious
work, a stringent algorithm identified miR-
155 as the only microRNA with a target
site in the 30 UTR ofAicda. The responsive-
ness of the Aicda 30 UTR to repression by
miR-155 was validated in a transfection
assay. The authors next used a bacterial
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system to investigate what happens when
Aicda is relieved from regulation by miR-
155. Already in hand was a mouse strain
that carries a BAC transgene covering the
region surrounding the Aicda locus. The
transgene (termed AID-GFP) encodes an
AID-GFP fusion protein that retains cata-
lytic activity and rescues CSR in AID-defi-
cient B cells. The authors constructed
a similar indicator strain carrying a BAC
transgene (AID-GFP-Mut) in which the
miR-155 seed region was mutated. Mice
carrying the AID-GFP-Mut transgene dif-
fered from control animals carrying the
AID-GFP transgene with respect to induc-
tion of AID; moreover, mutation of the
miR-155 target site perturbed both CSR
and affinity maturation.
LPSand IL-4 inducedhigher amounts of
the AID-GFP fusion protein in primary
B cells from AID-GFP-Mut mice than in
B cells from mice bearing the AID-GFP
transgene. Moreover, against an AID-
deficient genetic background, the AID-
GFP-Mut transgene supported a higher
frequency of CSR in primary B cells
stimulated with LPS and IL-4 than did the
AID-GFP transgene. Thus mutation of the
miR-155 target site in the Aicda 30 UTR
proved to be of functional consequence.
Upon immunization of transgenic mice
with a T cell-dependent antigen, AID-
GFP was appropriately expressed in GC
B cells, although AID-GFP was more
highly expressed in mice bearing the mu-
tant transgene, Moreover, in AID-GFP-
Mut mice the AID fusion protein was
found in B cells circulating in blood, sug-
gesting that mutation of the miR-155 tar-
get site allows persistent expression of
AID after transit through GCs. Despite
overexpression of AID, the AID-GFP-Mut
mice showed no change in the frequency
or pattern of somatic hypermutation. This
result is in fact consistent with earlier indi-
cations that the amount of AID is not
limiting for somatic hypermutation. Sur-
prisingly, overexpression of AID in themu-
tant transgenic mice was associated with
impaired affinity maturation. The basis for
this result is unclear. Examination of circu-
lating B cells revealed greater clonal het-
erogeneity in AID-GFP-Mut mice than in
AID-GFP animals, as well as an increase
in the number of mutated clones lacking
specific sequence alterations associated
with affinity maturation. As the authors in-
dicate, this observation is most consistentwith the possibility that in animals persis-
tently expressing AID, low-affinity cells
somehow escape the GC. The data do
not exclude the possibility—not exclusive
of the first—that some cells mutate away
from higher affinity through the continuing
action of AID. In either event, the impair-
ment of affinity maturation in the AID-
GFP-Mut mice remains mysterious.
Dorsett and coworkers (Dorsett et al.,
2008) constructed amouse strain in which
Figure 1. A Pathway Leading to Repression
of AID by miR-155
Steps in the biogenesis of miR-155 are dia-
grammed. Immune stimuli that induce Bic, the
pri-miR-155, are listed at upper left. Dashed
arrows indicate possible points at which genera-
tion of miR-155 from Bic may be suppressed in
Burkitt’s lymphoma. AID and PU.1 are indicated
below as validated targets of miR-155. Also indi-
cated is bcl-6, a potential miR-155 target that
exerts a suppressive effect on p53; repression of
bcl-6 bymiR-155 is thus predicted to be anti-onco-
genic. Effects observed by Teng et al. (2008) and
Dorsett et al. (2008) upon release of AID from
repression by miR-155 are indicated at lower right.Immthe seed-match nucleotides of the puta-
tive miR-155 target site in Aicda are
mutated (Aidca155). The authors bred the
resulting animals to AID-deficient mice
to obtain Aidca155/ heterozygotes. B
cells developed normally, but when mice
were treated with LPS and IL-4, AID pro-
tein and mRNA accumulated to higher
amounts in Aidca155/ mice than in
Aidca+/ controls; the half-life of Aicda
mRNA was prolonged by 2-fold in
Aidca155/ B cells. These observations
imply that miR-155 regulates AID expres-
sion by promoting the degradation of
Aicda mRNA. Consistent with the results
of Teng et al., Aidca155/ B cells exhibited
a higher frequency of CSR than Aidca+/
B cells and exhibited no substantial
increase in somatic hypermutation.
The most stunning consequence of the
Aidca155 mutation, however, is its associ-
ation with chromosomal translocations
involving the Myc and Igh loci. The result
can be appreciated in the context of an
earlier study in which AID was shown to
be essential for the Myc-Igh transloca-
tions that accompany expression of an
IL-6 transgene (Ramiro et al., 2004). In
the present study, ex vivo treatment of B
cells from Aidca155/ mice with LPS- and
IL-4-induced Myc-Igh translocations at
a frequency 3–6 times greater than in B
cells from Aidca+/ mice. An even greater
increase in Myc-Igh translocation fre-
quency (about 15-fold) was seen in B cells
deficient inmiR-155, suggesting thatmiR-
155 counteracts genomic instability by
some means in addition to AID repres-
sion. Nonetheless, Aidca155/ and miR-
155-deficient mice do not show an in-
crease in the incidence of B cell tumors.
Thus, although the available data indicate
that miR-155 can act as a suppressor of
Myc-Igh translocations, relief of this
suppressive mechanism seems insuffi-
cient to promote frank malignancy. These
observations are provocative in light of
the paucity of miR-155 in Burkitt’s lym-
phoma, in which Myc-Igh translocations
are typical.
The ability of the Aidca155 mutation to
promote chromosomal translocation in
the absence of increased somatic hyper-
mutation is consistent with the interpreta-
tion that factors other than AID might be
limiting for somatic hypermutation. Indeed,
deamination by AID is not always accom-
panied by extensive mutagenesis; on the
contrary, the introduction of mutationsunity 28, May 2008 ª2008 Elsevier Inc. 597
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restricted to a subset of sites upon which
AID acts (Liu et al., 2008). Thus mutation
is not an obligate consequence of AID
activity. TheAidca155/mouse further sug-
gests that in some settings AID might pro-
mote genomic instability in the absence of
obvious mutagenesis.
The demonstration that miR-155 re-
presses the expression of AID—or indeed
that any miRNA represses any other tran-
script—provokes consideration of how
the processing of pri- and pre-miRNAs is
regulated and how transcription of pri-
miRNAs is controlled. Engagement of sur-
face Ig induces Bic transcripts in B cells,
but accumulation of miR-155 is not nec-
essarily correlated with accumulation of
its pri-miRNA (Kluiver et al., 2007). Clearly,
we have much to learn before we can un-
derstand how the abundance of miR-155Anergic Signals: T
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The molecular mechanisms that und
(2008) report that anergy may occur
Immune tolerance of T cells to self-
antigen is achieved through multiple
mechanisms (Schwartz, 2003). In addition
to the existence of negative selection
in the thymus, autoreactive T cells that
evade thymic deletion are functionally
silent in the periphery via anergy or
extracellular suppression by environment
factors such as regulatory T cells. T cell
anergy represents a state of cells that
cannot give rise to a productive response
upon stimulation with antigen. Although
anergic cells exhibit a systemic impair-
ment in multiple T cell receptor (TCR)
downstream signaling pathways, the pre-
cise defect in the TCR signaling cascade
and molecular mechanisms leading to
such a defect remain unclear.
In this issue of Immunity, Teague et al.
(2008) have provided new insights into
598 Immunity 28, May 2008 ª2008 Elsevieris governed. Until then, we are left with
the question posed by the Roman satirist
Juvenal: ‘‘Quis custodiet ipsos custo-
des?’’—‘‘Who watches the watchers?’’
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